Development of novel vaccine vectors: Chimpanzee adenoviral vectors

Guo, Jingao; Mondal, Moumita; Zhou, Dongming

doi:10.1080/21645515.2017.1419108

Cited by 61 publications

(55 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[6][7][8] Recently, new methods, such as direct ligation after digestion with rare-cutter restriction enzyme (especially homing endonuclease), 9 site-specific recombination, bacterial artificial chromosome-based recombination, and even DNA assembly, have been used to construct adenoviral vectors. [10][11][12] Several DNA assembly methods are used across the synthetic biology community, among which the most used method is isothermal or Gibson assembly (after Daniel Gibson who developed the technique). [13][14][15] In a Gibson assembly reaction, T5 exonuclease, thermostable high-fidelity DNA polymerase, and Taq DNA ligase are combined in a cocktail with overlapping fragments of double-stranded DNA.…”

Section: Introductionmentioning

confidence: 99%

Single Plasmid-Based, Upgradable, and Backward-Compatible Adenoviral Vector Systems

Liu¹,

Zhang

et al. 2019

Human Gene Therapy

View full text Add to dashboard Cite

Existing adenoviral vector systems have two drawbacks. It is labor-intensive and time-consuming to load a transgene in these systems, and transgene-harboring vectors are dead ends: they cannot be reused to construct a vector carrying another transgene or achieving new characteristics. To conquer these shortcomings, single plasmid-based adenoviral vector systems were constructed where a unique PmeI site was located at the position for insertion of the exogenous gene. The polymerase chain reaction (PCR) amplified transgene could be cloned into PmeI-linearized starting plasmids using one step of Gibson assembly to generate target adenoviral plasmids, which were then ready for virus rescue. This procedure was termed restriction assembly. To expand the application of these systems, two ClaI sites were created upstream and downstream of the fiber gene to generate an upgraded starting plasmid pKAd5f11pABR-EPG. The modified fiber gene, amplified by overlap extension PCR, could be used to substitute the original fiber in pKAd5f11pABR-EPG to generate an adenoviral plasmid with a new fiber by restriction assembly. On the other hand, pKAd5f11pABR-EPG was also a starting adenoviral plasmid for expressing other transgenes.In conclusion, easy-to-use and upgradable adenoviral vector systems are introduced here, which offer extensive versatility and can serve as a basic platform and functional component library for the synthetic biology of adenoviral vectors.

show abstract

Section: Introductionmentioning

confidence: 99%

Single Plasmid-Based, Upgradable, and Backward-Compatible Adenoviral Vector Systems

Liu¹,

Zhang

et al. 2019

Human Gene Therapy

View full text Add to dashboard Cite

show abstract

“…Human and animal adenovirus infections are very common, and the majority of the population of host species contain neutralizing antibodies against the most prevalent serotypes of adenoviruses. Both human and non-human adenoviruses have been studied extensively and are the basis of adenoviral vector-based vaccine and gene therapies [18,19]. In humans, infection by non-human adenovirus serotypes is not common.…”

Section: Genome and Proteinsmentioning

confidence: 99%

“…These properties of adenoviruses encouraged researchers to use non-human adenoviruses as gene or vaccine antigen delivery vectors to mitigate the pre-existing neutralizing immunity that commonly exists against human adenoviral vectors. Several non-human adenoviruses such as bovine Ad serotype 3 (BAd3); canine Ad serotype 2 (CAd2); chimpanzee Ad serotypes 1, 2, 3, 5, 6, 7 and 68 (ChAd1, ChAd2, ChAd3, ChAd5, ChAd6, ChAd7, ChAd68); ovine Ad serotype 7 (OAd7); porcine Ad serotype 3 and 5 (PAd3, PAd5); and fowl Ad serotypes 1, 8, 9, and 10 (FAd1, FAd8, FAd9, FAd10) are currently being tested as vaccine or gene delivery vectors [18,[20][21][22]. Extensive research in the molecular biology of both human and non-human Ads has helped in better understanding of the adenoviruses and designing of adenoviral vectors.…”

Section: Genome and Proteinsmentioning

confidence: 99%

“…This allowed for repeated vaccination and also vaccination in individuals with pre-existing vector immunity [145][146][147][148][149]. Currently, a number of non-human adenoviral vectors such as chimpanzee and bovine are also being utilized to avoid pre-existing vector-specific immunity [18,21,[150][151][152].…”

Section: Adenoviral Vector (Biologic)mentioning

confidence: 99%

“…The human population lack nAbs against these adenoviruses, and therefore, the vectors derived from these adenoviruses could be more efficacious in comparison to HAd and ChAd. The mouse models with experimentally induced pre-existing immunity by the administration of HAd vector demonstrated a lack of nAbs and CD4 + T cells against PAd3 and BAd3 [18]. Furthermore, BAd3-or PAd3-based influenza virus vaccine demonstrated high efficacy even in the presence of pre-existing HAd5 immunity.…”

Section: Use Of Alternative Less Frequent Adenoviruses For Vectormentioning

confidence: 99%

See 2 more Smart Citations

Adenoviral Vector-Based Vaccines and Gene Therapies: Current Status and Future Prospects

Singh¹,

Kumar²,

Agrawal³

2019

Adenoviruses

View full text Add to dashboard Cite

Adenoviruses are one of the most genetically diverse DNA viruses and cause non-lifethreatening infections in the ocular, respiratory, or gastrointestinal epithelium of a diverse range of hosts. Adenoviruses are excellent vectors for delivering genes or vaccine antigens to the target host tissues and are being tested in several vaccine and gene therapy studies. Adenovirus-based vectors offer several advantages over other viral vectors such as broad range of tissue tropism, well-characterized genome, ease of genetic manipulation including acceptance of large transgene DNA insertions, inherent adjuvant properties, ability to induce robust transgene-specific T cell and antibody responses, non-replicative nature in host, and ease of production at large scale. However, several studies have highlighted major drawbacks to using adenovirus as vaccine and gene therapy vectors. These include pre-existing immunity in humans, inflammatory responses, sequestering of the vector to liver and spleen, and immunodominance of the vector genes over transgenes. In the same vein, recently discovered protein sequence homology and heterologous immunity between adenoviruses and hepatitis C virus have significant implications in the use of adenoviral vectors for vaccine development, especially for hepatitis C virus. This chapter focuses on the current scope and challenges in using adenoviral vector-based vaccines and gene therapies.

show abstract

Viral vector‐based gene therapies in the clinic

Zhao

Anselmo

Mitragotri

2021

Bioengineering & Transla Med

132

View full text Add to dashboard Cite

Gene therapies are currently one of the most investigated therapeutic modalities in both the preclinical and clinical settings and have shown promise in treating a diverse spectrum of diseases. Gene therapies aim at introducing a gene material in target cells and represent a promising approach to cure diseases that were thought to be incurable by conventional modalities. In many cases, a gene therapy requires a vector to deliver gene therapeutics into target cells; viral vectors are among the most widely studied vectors owing to their distinguished advantages such as outstanding transduction efficiency. With decades of development, viral vector‐based gene therapies have achieved promising clinical outcomes with many products approved for treating a range of diseases including cancer, infectious diseases and monogenic diseases. In addition, a number of active clinical trials are underway to further expand their therapeutic potential. In this review, we highlight the diversity of viral vectors, review approved products, and discuss the current clinical landscape of in vivo viral vector‐based gene therapies. We have reviewed 13 approved products and their clinical applications. We have also analyzed more than 200 active trials based on various viral vectors and discussed their respective therapeutic applications. Moreover, we provide a critical analysis of the major translational challenges for in vivo viral vector‐based gene therapies and discuss possible strategies to address the same.

show abstract

Development of novel vaccine vectors: Chimpanzee adenoviral vectors

Cited by 61 publications

References 57 publications

Single Plasmid-Based, Upgradable, and Backward-Compatible Adenoviral Vector Systems

Single Plasmid-Based, Upgradable, and Backward-Compatible Adenoviral Vector Systems

Adenoviral Vector-Based Vaccines and Gene Therapies: Current Status and Future Prospects

Viral vector‐based gene therapies in the clinic

Contact Info

Product

Resources

About